We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
IDT Australia Limited is a drug manufacturers-specialty & generic business based in Australia. IDT Australia shares (IDT) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. IDT Australia has a trailing 12-month revenue of around $16.9 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $0.16 - $0.755 |
|---|---|
| 50-day moving average | $0.6188 |
| 200-day moving average | $0.4348 |
| Target price | $0.08 |
| PE ratio | 62.2222 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.009 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.59
| 1 week (2021-10-19) | -0.84% |
|---|---|
| 1 month (2021-09-24) | -10.61% |
| 3 months (2021-07-26) | 53.25% |
| 6 months (2021-04-26) | 51.28% |
| 1 year (2020-10-26) | 257.58% |
|---|---|
| 2 years (2019-10-25) | 257.58% |
| 3 years (2018-10-26) | 257.58% |
| 5 years (2016-10-26) | 174.42% |
Valuing IDT Australia stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IDT Australia 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
IDT Australia 's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 62x. In other words, IDT Australia shares trade at around 62x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
IDT Australia 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.6 million (£0.0 million).
The EBITDA is a measure of a IDT Australia 's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $16.9 million |
|---|---|
| Operating margin TTM | 5.71% |
| Gross profit TTM | $15.1 million |
| Return on assets TTM | 1.93% |
| Return on equity TTM | 8.26% |
| Profit margin | 12.42% |
| Book value | 0.115 |
| Market capitalisation | $134.3 million |
TTM: trailing 12 months
We're not expecting IDT Australia to pay a dividend over the next 12 months.
IDT Australia 's shares were split on 15 April 2010.
Over the last 12 months, IDT Australia 's shares have ranged in value from as little as $0.16 up to $0.755. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while IDT Australia 's is 0.4609. This would suggest that IDT Australia 's shares are less volatile than average (for this exchange).
IDT Australia Limited researches, develops, manufactures, and sells active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally. The company offers analytical method development, stability chambers, and chemistry and microbiology quality control laboratory services. Its services also include project management, chemical, analytical chemistry, pharmacy, clinical packaging, and regulatory affairs, as well as pharmaceutical development services in all dosage forms. In addition, the company offers medicinal cannabis products; and various contract manufacturing services. IDT Australia Limited was founded in 1975 and is headquartered in Boronia, Australia.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Shares in the wealth management giant have been largely stable in the last 6 months.
Everything we know about the Judo Capital Holdings IPO, plus information on how to buy in.
Everything we know about the Alloggio Group IPO, plus information on how to buy in.
Everything we know about the Larvotto Resources IPO, plus information on how to buy in.
Everything we know about the Vulcan Steel IPO, plus information on how to buy in.
Everything we know about the Artrya IPO, plus information on how to buy in.
Everything we know about the 8 Au IPO, plus information on how to buy in.
Everything we know about the Radiopharm Theranostics IPO, plus information on how to buy in.
The online retailer’s shares have lost more than half their value in the last 12 months.
